Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Transcult Nurs ; 34(5): 375-388, 2023 09.
Article in English | MEDLINE | ID: mdl-37431805

ABSTRACT

OBJECTIVE: There are approximately 231,000 women detained daily within the nation's jail and prison systems with women of color making up nearly half of those experiencing incarceration. The purpose of this scoping review was to synthesize the literature on the reproductive autonomy of Black women influenced by incarceration, using the three tenets of reproductive justice. METHODS: We searched PubMed, CINAHL, SocINDEX, and PsycINFO for research related to reproductive justice written in English and published in the United States from 1980 to 2022. A review of 440 article titles and abstracts yielded 32 articles for full-text review; nine articles met inclusion. RESULTS: Eight addressed Tenet 1; five mentioned Tenet 2; none addressed Tenet 3. Recognition of the influence of incarceration on the reproductive autonomy of Black women is limited. CONCLUSION: The findings from this review suggest a need to address (a) reproductive choice, (b) support goals, and (c) support of justice-involved Black women.


Subject(s)
Black People , Correctional Facilities , Personal Autonomy , Prisoners , Reproductive Rights , Female , Humans , Correctional Facilities/ethics , Reproductive Rights/ethics , United States , Social Justice
2.
Subst Abus ; 41(2): 150-154, 2020.
Article in English | MEDLINE | ID: mdl-31800376

ABSTRACT

Opioid use disorder (OUD) is highly prevalent among persons who are incarcerated. Medication treatment for opioid use disorder (MOUD), methadone, buprenorphine, and naltrexone, is widely used to treat OUD in the community. Despite MOUD's well-documented effectiveness in improving health and social outcomes, its use in American jails and prisons is limited.Several factors are used to justify limited access to MOUD in jails and prisons including: "uncertainty" of MOUD's effectiveness during incarceration, security concerns, risk of overdose from MOUD, lack of resources and institutional infrastructure, and the inability of people with OUD to provide informed consent. Stigma regarding MOUD also likely plays a role. While these factors are relevant to the creation and implementation of addiction treatment policies in incarcerated settings, their ethicality remains underexplored.Using ethical principles of beneficence/non-maleficence, justice, and autonomy, in addition to public health ethics, we evaluate the ethicality of the above list of factors. There is a two-fold ethical imperative to provide MOUD in jails and prisons. Firstly, persons who are incarcerated have the right to evidence-based medical care for OUD. Secondly, because jails and prisons are government institutions, they have an obligation to provide that evidence-based treatment. Additionally, jails and prisons must address the systematic barriers that prevent them from fulfilling that responsibility. According to widely accepted ethical principles, strong evidence supporting the health benefits of MOUD cannot be subordinated to stigma or inaccurate assessments of security, cost, and feasibility. We conclude that making MOUD inaccessible in jails and prisons is ethically impermissible.


Subject(s)
Correctional Facilities/ethics , Health Services Accessibility/ethics , Opiate Substitution Treatment/ethics , Opioid-Related Disorders/drug therapy , Prisoners , Analgesics, Opioid/therapeutic use , Beneficence , Buprenorphine/therapeutic use , Evidence-Based Practice , Humans , Mental Health Services , Methadone/therapeutic use , Naltrexone/therapeutic use , Narcotic Antagonists/therapeutic use , Personal Autonomy , Public Health/ethics , Social Justice
SELECTION OF CITATIONS
SEARCH DETAIL
...